1 Du HY, Lin Y. Translational medicine research improves individual drug research and development. Drug Evaluation, 2011, 8(16): 4-7.
2 Murthy SC, Reznik SI, Ogwudu UC, et al. Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung. Ann Thorac Surg, 2010, 90(4): 1067-74.
3 Adams JU. Building the bridge from bench to bedside. Nat Rev Drug Discov, 2008, 7(6): 463-4.
4 Ciccimaro E, Blair IA. Stable-isotope dilution LC-MS for quantitative biomarker analysis. Bioanalysis, 2010, 2(2): 311-41.
5 Zamboni N, Saghatelian A, Patti GJ. Defining the metabolome: size, flux, and regulation. Mol Cell, 2015, 58(4): 699-706.
6 MacIntyre DA, Jim6nez B, Lewintre E, et al. Serum metabolome analysis by 1 H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia, 2010, 24(4): 788-97.
7 Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009, 457(7231): 910-4.
8 Chen J, Zhang X, Cao R, et al. Serum 27-nor-513-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J Proteome Res, 2011, 10(5): 2625-32.
9 Zhu T. Analysis on differentially expressed protein in serum of patients with ovarian cancer. Suzhou, Soochow Uniersity, 2010.
10 Hossain M, Kaleta DT, Robinson EW, et al. Enhanced sensitivity for selected reaction monitoring mass spectrometry-based targeted proteomics using a dual stage electrodynamic ion funnel interface. Mol Cell Proteomics, 2011, 10(2): M000062-MCP201.
11 Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science, 1991, 253(5015): 49-53.
12 Ren J, Li G, Ge J, et al. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum, 2012, 55(8): 913-23.
13 Riely GJ, Yu HA. EGFR: The paradigm of an oncogene-driven lung cancer. Clin Cancer Res, 2015, 21(10): 2221-6.
14 Bayele HK, Chiti A, Colina R, et al. Isotopic biomarker discovery and application in translational medicine. Drug Discov Today, 2010, 15(3-4): 127-36.
15 van Gool AJ, Henry B, Sprengers ED. From biomarker strategies to biomarker activities and back. Drug Discovery Today, 2010, 15(3): 121-6.
17 Hargreaves RJ, Rabiner EA. Translational PET imaging research. Neurobiol Dis, 2014, 61: 32-8.
18 Poste G. Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. Trends Mol Med, 2012, 18(12): 717-22.
19 Fan ZJ, Wang W. Sub-network exploration of disease-associated proteins based on greedy algorithm. Microcomputer Information, 2010, 26(23): 188-9.
20 Mueller T, Leitner I, Egger M, et al. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin Chim Acta, 2015, 445: 155-60.
21 Chen H, Song Z, Qian M, et a1. Selection of disease-specific biomarkers by integrating inflammatory mediators with clinical informatics in AECOPD patients：a preliminary study. J Cell Mol Med, 2012, 16(6): 1286-97.
22 Marko-Varga G, V69vafi A, Rezeli M, et al. Understanding drug uptake and binding within targeted disease microenvironments in patients: a new tool for translational medicine. Clin Transl Med, 2012, 1(1): 8.
23 Hayes RL, Robinson G, Muller U, et al. Translation of neurological biomarkers to clinically relevant platforms. Methods Mol Biol, 2009, 566: 303-13.
24 Lopez E, Madero L, Lopez-Pascual J, et al. Clinical proteomics and OMICS clues useful in translational medicine research. Proteome Sci, 2012, 10(1): 35.
25 Skates SJ, Gillette MA, LaBaer J, et al. Statistical design for biospecimen cohort size in proteomics-basedbiomarker discovery and verification studies. J Proteome Res, 2013, 12(12): 5383-94.
26 Sathi S, Mahapatra H, Sunder S, et al. Nontraditional cardiovascular biomarkers and estimation ofcardiovascular risk in predialysis chronic kidney disease patients and their correlations with carotid intima media thickness. Nephrourol Mon, 2014, 6(6): e22112.
27 Mathew JP, Taylor BS, Bader GD, et al. From bytes to bedside: data integration and computational biology for translational cancer research. PLoS Comput Biol, 2007, 3(2): e12.
28 Vergnenegre A, Corre R, Lena H, et al. How old is "too old" for translational research? Transl Lung Cancer Res, 2014, 3(2): 116-9.